Metered Dose Inhaler Devices Market Size
The global metered dose inhaler devices market was valued at approximately USD 16.28 billion in 2025 and is projected to reach USD 28.16 billion by 2035, expanding at a CAGR of 6.2% during the forecast period. The market is gaining momentum as the rising prevalence of asthma and chronic obstructive pulmonary disease (COPD), widespread use of inhalation therapy, physician preference for MDIs, and availability of generic inhalers continue to support demand. Technological advancements are also strengthening the market, with increasing focus on smart dose tracking, breath-actuated inhalation technology, compact portable designs, improved dose accuracy, and eco-friendly propellants.
The competitive opportunity is increasingly focused on patient-friendly, connected, accurate, and environmentally sustainable inhalation devices. The growing burden of COPD and other respiratory conditions is expanding the need for convenient drug-delivery systems, while the shift toward homecare treatment is creating additional opportunities for portable and digitally enabled inhalers. Manufacturers are increasingly exploring smart inhalers, digital adherence monitoring, advanced portable devices, and lower-impact propellant technologies to improve treatment convenience and support long-term respiratory disease management. The market is therefore shifting toward connected inhalation technologies, enhanced dose delivery, portability, home-based care, and environmentally conscious device development, supporting continued growth in the global Metered Dose Inhaler Devices Market.
A metered-dose inhaler (MDI) is a pressurized inhaler that delivers medication using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.
Metered Dose Inhaler Devices Market Scope
| Metric | Details |
| Market Size in 2025 | USD 16.28 billion |
| Market Size by 2035 | USD 28.16 billion |
| CAGR | 6.20% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | By Product Type, By Medications, By Application, By Distribution Channel, and By Region |
| Leading Region | North America |
| Fastest Growing Region | Asia Pacific |
For more insights - Download the Sample
Metered Dose Inhaler Devices Market Dynamics
The market for metered dose inhalers is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments, and the rising investment in healthcare infrastructure in emerging markets.
The rising adoption of breathing-actuated inhalers and increasing investment in research and development are expected to drive the market’s growth.
The metered dose inhaler market is driven by rising advancements in technology, an increase in demand for metered dose inhalers, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.
Technological advances have resulted in increasing metered dose inhaler adoption. The rising number of respiratory disorders, and increasing awareness among people about advanced respiratory devices like bronchodilators inhalers and bronchodilators inhalers for respiratory disorders, which have beneficial features over the traditional treatment methods, and rising healthcare expenditure by governments and the private sector, could lead to higher infrastructure investments and drive the metered dose inhaler market.
Various novel product launches and research studies contribute to the market’s growth. For instance, on May 17, 2022, Teva Pharmaceuticals, a Teva Pharmaceutical Industries Ltd. affiliate, announced its novel study findings based on the usage of short-acting beta agonist (SABA)’s novel established clinical thresholds that highlight real-world use of SABA in asthma patients in the U.S. and the potential for a digital inhaler, ProAir Digihaler (albuterol sulfate) inhalation powder.
The environmental or side effects associated with metered-dose inhalers are expected to hamper the market’s growth.
However, metered dose inhalers release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA) biohazard nature propellants, which negatively impact the metered dose inhalers market’s growth.
Stringent rules and regulations for approval of these metered dose inhalers and adverse events such as trembling, palpitations, nervous tension, muscle cramps, and others linked with bronchodilators hinder the market growth.
COVID-19 Impact on Metered Dose Inhaler Devices Market Growth
The pandemic has negatively impacted global financial expectations, operations, and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The metered dose inhaler market has experienced huge losses due to COVID as various research and clinical trials got postponed due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations, and mergers are happening worldwide, boosting the market’s growth. For instance, on December 17, 2021, Amgen announced that AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.
Market Segment Analysis
The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2026-2035)
The bronchodilators segment is the highest market holder in the global metered dose inhaler market. The global metered dose inhaler market is segmented based on medications in corticosteroids, bronchodilators, and combinations (corticosteroids & bronchodilators). The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.
These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, on July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long‑acting beta2‑agonist (LABA), who experienced asthma exacerbations.
Market Geographical Share
North America holds the largest market share in the global metered dose inhaler market.
North America dominates the global metered dose inhaler market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults in the United States suffered from chronic obstructive pulmonary disease (COPD) in 2020. And 25 million had asthma.
Increasing expenditure on healthcare and raising awareness among people are also contributing to the market’s growth in this region. Advancement of medications of metered dose inhalers in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the metered dose inhaler market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, on September 21, 2020, Teva Respiratory, LLC., Teva Pharmaceutical Industries Ltd. affiliate announced the launch of two digital maintenance inhalers AirDuo Digihaler (salmeterol and fluticasone propionate) and ArmonAir Digihaler (fluticasone propionate) inhalation powder, for patients with asthma. AirDuo Digihaler is a prescription medicine used to prevent wheezing and control asthma symptoms in people 12 years and older.
Market Companies and Competitive Landscape
The metered dose inhaler market is highly competitive with local and global companies’ presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, on April 9, 2020, Cipla Limited announced receiving final approval from the United States Food and Drug Administration (US FDA) for its inhalation aerosol, Albuterol Sulfate 90mcg (base)/actuation’s abbreviated new drug application (ANDA). This is Cipla’s first AB-rated generic therapeutic similar version of Proventil HFA Inhalation Aerosol of Merck Sharp & Dohme Corp’s. It is utilized for treating acute episodes of bronchospasm or asthmatic symptoms prevention.
Novartis AG.
Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative Medicines and Sandoz for biosimilars and generic pharmaceuticals.
Product Portfolio:
Proventil HFA: Proventil HFA (albuterol sulfate) inhalation aerosol is used for reversible obstructive airway disease, like asthma, and to treat or prevent bronchospasm in patients four years and older.
Key Developments
July 2026: The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the world's first lower-carbon pressurized metered-dose inhalers (pMDIs) using the next-generation propellant HFA-152a. The new inhalers are expected to become available in the UK later in 2026, representing a major step toward reducing the environmental impact of pMDIs while maintaining established inhaler-based treatment.
June 2026: Metered-dose inhaler technology continued receiving strong industry attention, with the market emphasizing advances in device development, manufacturing processes, formulation technologies, and regulatory changes. A dedicated 2026 MDI technology program highlighted the industry's continued focus on improving device performance while adapting to evolving regulatory and sustainability requirements.
May 2026: AstraZeneca highlighted the continued importance of pressurised metered-dose inhalers (pMDIs) in asthma and COPD management, while emphasizing the need to reduce their environmental footprint. The company noted that pMDIs account for a substantial share of inhaled therapy use and identified lower-carbon inhaler technologies as an important pathway toward more sustainable respiratory care.
April 2026: The global respiratory inhaler devices market continued to show strong demand for metered-dose inhalers, which were projected to account for 71.6% of product demand in 2026. Established prescribing patterns, extensive use in rescue therapy, and familiarity among physicians and patients continued to support the leading position of MDIs across respiratory care.
March 2026: GSK's next-generation Ventolin (salbutamol) MDI remained a key example of the industry's transition toward lower-carbon inhalation technologies. Phase III results confirmed therapeutic equivalence and comparable safety between the HFA-152a formulation and the existing HFA-134a version, while the new formulation has the potential to reduce greenhouse-gas emissions by 92% per inhaler. GSK indicated that regulatory submissions would support a planned launch from 2026.
The global metered dose inhaler market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.
